Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 24;6:e2100176. doi: 10.1200/CCI.21.00176

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — Feature analysis in OCH training data set. For clinically important features, the proportion of features included in each risk group was determined. The left column shows OS and the right column shows cancer progression. What attributes each risk group was composed of was shown: (A) age, (B) sex, (C) T-category, (D) pleural contact, (E) tumor texture, (F) histology, (G) PS, (H) CCI, and (I) BED₁₀ of maximum dose. Ad, adenocarcinoma; BED₁₀, biological effective dose at alpha/beta of 10; CCI, Charlson comorbidity index; GGO, ground-glass opacity; LCC, large cell carcinoma; NSCLC, non–small-cell lung cancer; OCH, Ofuna Chuo Hospital; OS, overall survival; PS, performance status; SCC, squamous cell carcinoma.

FIG 4. — Feature analysis in OCH training data set. For clinically important features, the proportion of features included in each risk group was determined. The left column shows OS and the right column shows cancer progression. What attributes each risk group was composed of was shown: (A) age, (B) sex, (C) T-category, (D) pleural contact, (E) tumor texture, (F) histology, (G) PS, (H) CCI, and (I) BED₁₀ of maximum dose. Ad, adenocarcinoma; BED₁₀, biological effective dose at alpha/beta of 10; CCI, Charlson comorbidity index; GGO, ground-glass opacity; LCC, large cell carcinoma; NSCLC, non–small-cell lung cancer; OCH, Ofuna Chuo Hospital; OS, overall survival; PS, performance status; SCC, squamous cell carcinoma.